Down‐regulated SPARCL1 is associated with clinical significance in human gastric cancer

Li, Ping; Qian, Ji; Yu, Guanzhen; Chen, Ying; Liu, Ke; Li, Jie; Wang, Jiejun

doi:10.1002/jso.22025

Cited by 29 publications

(38 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no deletion or mutation that might be responsible for the downregulation of SPARCL1 was found in NSCLC (Isler et al, 2004) and the promoter hypermethylation was also not the key mechanism by which SPARCL1 expression was repressed in pancreatic cancer cells (Esposito et al, 2007). In our previous work, no methylation variable positions and no mutation were observed in gastric cancer but a possible mechanism involving the loss of heterozygosity of SPARCL1 gene was revealed (Li et al, 2012). The specific mechanism for SPARCL1 downregulation in human breast cancer need further confirmed.…”

Section: Discussionmentioning

confidence: 76%

“…In the growth and proliferation of various tumor cells, SPARCL1 often presents decreased expression as a negative regulative factor, which may be closely related to the increase of the cell proliferation activity and the cell cycle progression (Claeskens et al, 2000). Particularly, growing evidence shows that SPARCL1 often presents a reduced or absent expression pattern in a variety of human tumor tissues (Bendik et al, 1998;Nelson et al, 1998;Isler et al, 2004;Esposito et al, 2007;Zaravinos et al, 2011;Hurley et al, 2012;Li et al, 2012). However, several studies have also found that an increased expression of SPARCL1 in a few of other type of human tumors derived from liver (Lau et al, 2006), uterus (Mencalha et al, 2008), and colon and rectum (Zhang et al, 2011;Hu et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…Sections were considered positive for SPARCL1 staining when more than 30% of tumor cells were stained moderately or strongly in the cell cytoplasm (Li et al, 2012).…”

Section: Evaluation Of Immunostainingmentioning

confidence: 99%

“…SPARCL1 is expressed in many tissues and organs such as heart, lung, brain, bone, muscle, colon and lymphatic gland, but it has a lower expression in pancreas, spleen, thyroid gland and placental tissue and even SPARCL1 is not expressed in liver, kidney and peripheral blood leucocytes (Girard and Springer, 1995;Hambrock et al, 2003). Recently, a few of studies have reported that SPARCL1 was down-regulated in a wide variety of human malignancies including lung cancer (Bendik et al, 1998;Isler et al, 2004), prostate cancer (Nelson et al, 1998;Hurley et al, 2012), pancreatic cancer (Esposito et al, 2007), and gastric cancer (Li et al, 2012), and might play a role as a tumor suppressor gene (Claeskens et al, 2000). However, little is known about the expression and significance of SPARCL1 in human breast cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

Cao¹,

Kuo²,

Zhu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Secreted protein acidic and rich in cysteines-like protein 1 (SPARCL1), an extracellular matrix glycoprotein, has been implicated in the pathogenesis of several disorders including cancer. However, little is known about the expression and significance of SPARCL1 in human breast cancer. The aim of this study was to determine the expression pattern and clinicopathological significance of SPARCL1 in a Chinese breast cancer cohort. mRNA and protein expression of SPARCL1 in human breast cancer cell lines and breast cancer tissues was detected using the reverse transcription-polymerase chain reaction, real-time quantitative PCR, and Western blotting, respectively. Immunostaining of SPARCL1 in 282 Chinese breast cancer samples was examined and associations with clinicopathological parameters were analyzed. Compared to the positive expression in immortalized human breast epithelial cells, SPARCL1 was nearly absent in human breast cancer cell lines. Similarly, a significantly reduced expression of SPARCL1 was observed in human breast cancer tissues compared to that in normal breast epithelial tissues, for both mRNA and protein levels (P < 0.001). Immunohistochemical analysis showed that strong cytoplasmic immunostaining of SPARCL1 was observed in almost all normal breast samples (43/45) while moderate and strong immunostaining of SPARCL1 was only detected in 191 of 282 (67.7%) breast cancer cases. Moreover, down-regulation of SPARCL1 was significantly correlated with lymphatic metastasis (P = 0.020) and poor grade (P = 0.044). In conclusion, SPARCL1 may be involved in the breast tumorigenesis and serve as a promising target for therapy of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

“…Sections were considered positive for SPARCL1 staining when more than 30% of tumor cells were stained moderately or strongly in the cell cytoplasm (Li et al, 2012).…”

Section: Evaluation Of Immunostainingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

Cao¹,

Kuo²,

Zhu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Of the studies examining the expression of SPRL1 in tumor, downregulation of this protein was reported in metastatic prostate adenocarcinoma, 36 non-small cell lung cancer, 37 and gastric cancer. 38 Notably, in the study of Li and colleagues, SPRL1 positive patients exhibited a better median survival than SPRL1-negative patients. Up-regulation of SPRL1 was observed in pancreatic cancer, 39 colorectal adenocarcinomas, 40 and hepatocellular cancer.…”

Section: ■ Discussionmentioning

confidence: 97%

Sparc-Like Protein 1 Is a New Marker of Human Glioma Progression

et al. 2012

View full text Add to dashboard Cite

High-grade gliomas (glioblastomas) are the most common and deadly brain tumors in adults, currently with no satisfactory treatment available. Apart from de novo glioblastoma, it is currently accepted that these malignancies mainly progress from lower grade glial tumors. However, the molecular entities governing the progression of gliomas are poorly understood. Extracellular and membrane proteins are key biomolecules found at the cell-to-cell communication interface and hence are a promising proteome subpopulation that could help understand the development of glioma. Accordingly, the current study aims at identifying new protein markers of human glioma progression. For this purpose, we used glial tumors generated orthotopically with T98G and U373 human glioma cells in nude mice. This setup allowed also to discriminate the protein origin, namely, human (tumor) or mouse (host). Extracellular and membrane proteins were selectively purified using biotinylation followed by streptavidin affinity chromatography. Isolated proteins were digested and then identified and quantified employing 2D-nano-HPLC−MS/MS analysis. A total of 23 and 27 upregulated extracellular and membrane proteins were identified in the T98G and U373 models, respectively. Approximately two-thirds of these were predominantly produced by the tumor, whereas the remaining proteins appeared to be mainly overexpressed by the host tissue. Following extensive validation, we have focused our attention on sparc-like protein 1. This protein was further investigated using immunohistochemistry in a large collection of human glioma samples of different grades. The results showed that sparc-like protein 1 expression correlates with glioma grade, suggesting the possible role for this protein in the progression of this malignancy.

show abstract

Effect of ECM2 expression on bovine skeletal muscle‐derived satellite cell differentiation

Liu

Tong

et al. 2018

Cell Biology International

View full text Add to dashboard Cite

Extracellular matrix components have important regulatory functions during cell proliferation and differentiation. In recent study, extracellular matrix were shown to have a strong effect on skeletal muscle differentiation. Here, we aimed to elucidate the effects of extracellular matrix protein 2 (ECM2), an extracellular matrix component, on the differentiation of bovine skeletal muscle-derived satellite cells (MDSCs). Western blot and immunofluorescence analyses were used to elucidate the ECM2 expression pattern in bovine MDSCs during differentiation in vitro. CRISPR/Cas9 technology was used to activate or inhibit ECM2 expression to study its effects on the in vitro differentiation of bovine MDSCs. ECM2 expression was shown to increase gradually during bovine MDSC differentiation, and the levels of this protein were higher in more highly differentiated myotubes. ECM2 activation promoted MDSC differentiation, whereas its suppression inhibited the differentiation of these cells. Here, for the first time, we demonstrated the importance of ECM2 expression during bovine MDSC differentiation; these results could lead to treatments that help to increase beef cattle muscularity.

show abstract

Down‐regulated SPARCL1 is associated with clinical significance in human gastric cancer

Abstract: Our study revealed the clinical significance of SPARCL1 expression, providing a basis that the loss of SPARCL1 is a negative event in GC progression and prognosis. Furthermore, SPARCL1 protein might be considered to be a potential differentiation marker.

Cited by 29 publications

References 25 publications

Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

Sparc-Like Protein 1 Is a New Marker of Human Glioma Progression

Effect of ECM2 expression on bovine skeletal muscle‐derived satellite cell differentiation

Contact Info

Product

Resources

About